Related Experiment Video
Updated: Jun 28, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Combination therapy for malignant glioma based on PTEN status
Javier Gonzalez1, John de Groot
1University of Texas Medical Branch, MD Anderson Cancer Center, Galveston, TX 77555-0144, USA. javgonza@utmb.edu
Expert Review of Anticancer Therapy
|November 6, 2008
Summary
Targeting the phosphatidylinositol 3-kinase (PI3K)/Akt pathway shows limited success in glioma treatment due to pathway complexity. Combination therapies and strategic trial designs are crucial for overcoming resistance and improving outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Neuroscience
Background:
- The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is a critical regulator of cellular processes implicated in glioma development.
- Current targeted therapies focusing on this pathway have yielded modest clinical benefits in glioma patients.
- Gliomas exhibit complex signaling networks, leading to resistance against single-agent targeted therapies.
Purpose of the Study:
- To review the significance of the PI3K/Akt pathway in glioma.
- To explore the role of PTEN status in guiding targeted glioma therapies.
- To discuss the development of combination therapies and strategies for clinical trial design in malignant gliomas.
Main Methods:
- Literature review of PI3K/Akt pathway in glioma.
- Analysis of clinical trial data for targeted therapies.
- Discussion of PTEN status and its therapeutic implications.
- Exploration of combination therapy approaches and trial design strategies.
Main Results:
- The PI3K/Akt pathway is integral to glioma malignancy, affecting proliferation, survival, and metabolism.
- PTEN status may predict response to specific inhibitors like EGF receptor inhibitors.
- Glioma's inherent pathway redundancy necessitates combination strategies for effective treatment.
- Current trial designs may not adequately capture the complexities of pathway interactions.
Conclusions:
- Understanding the PI3K/Akt pathway and PTEN status is vital for effective glioma therapy.
- Combination therapies targeting multiple pathways are essential to overcome treatment resistance.
- Innovative clinical trial designs are required to accurately assess the efficacy of novel therapeutic strategies for malignant gliomas.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.